In a phase I clinical trial, 85 patients with heavily pretreated locally advanced and metastatic NSCLC patients were treated with MPDL-3280A, a humanized IgG1 monoclonal antibody against PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.